通心络胶囊治疗扩张性心肌病临床疗效及其机制研究

Clinical efficacy and mechanism of Tongxinluo Capsule in treatment of dilated cardiomyopathy

目的观察通心络胶囊治疗扩张性心肌病临床疗效及其机制研究。方法将本院治疗的90例扩张性心肌病患者按照治疗方式分为对照组与观察组各45例。对照组给予基础治疗,观察组在对照组治疗基础上给予通心络胶囊,对比两组患者心功能、血脂指标及N末端脑钠肽前体(NT-proBNP)、心肌肌钙蛋白I(cTnI)水平。结果观察组患者临床治疗有效率显著高于对照组(P<0.05);治疗后,两组左室射血分数(LVEF)较治疗提高,左室舒张末期腔径(LVEDD)、二尖瓣口舒张早期/晚期充盈峰值流速(E/A)均较治疗前降低且观察组治疗后LVEDD、E/A低于对照组,LVEF高于对照组(P<0.05);两组TC、TG、LDL-C、HDLC均较治疗前降低且观察组治疗后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)低于对照组(P<0.05);两组NT-proBNP、cTnI均较治疗前降低且观察组治疗后NT-proBNP、cTnI低于对照组(P<0.05)。结论通心络胶囊治疗扩张性心肌病患者,能够有效改善病情,改善心功能其作用机制在于改善血脂及心肌损伤,值得临床推广。

Objective To observe the clinical efficacy and mechanism of Tongxinluo Capsule in treatment of dilated cardiomyopathy.Methods 90 patients with dilated cardiomyopathy were divided into control group and observation group,with45 cases each.Control group was given basic treatment,observation group was given Tongxinluo Capsule on the basis of control group,compared the two groups with cardiac function,blood lipid index and N-terminal brain natriuretic peptide precursor(NTprobNP),cardiac troponin I(cTnI).Results The effective rate in observation group was higher than that in control group(P<0.05);after treatment,LVEF of left ventricular end-diastolic diameter(LVEDD) and mitral valve orifice early and late diastolic peak filling velocity(E/A) were both lower than those before treatment,and LVEDD and E/A of observation group were lower than those of control group,and LVEF was higher than that of control group(P<0.05),TC,TG,LDL-C and HDLC in both groups were all lower than those before treatment,and total cholesterol(TC) triglyceride(TG),low-density lipoprotein(LDL) and high-density lipoprotein(HDL) in observation group were lower than those in control group(P<0.05);nT-probNP,cTnI in both groups were lower than those before treatment,and those in observation group after treatment were lower than control group(P<0.05).Conclusion Tongxinluo Capsule can effectively improve the patients’ condition, improve the heart function in treatment of patients with dilated cardiomyopathy,its mechanism of action is to improve blood lipid and myocardial injury,which is worthy of clinical promotion.